Trial · NCT04925661
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Adverse Events | Through study completion, an average of 12 weeks. | To assess the safety and tolerability of therapy by incidence of treatment-emergent adverse events after multiple doses of HEC53856 capsule |
| Secondary | AUC0-t | Day 1(Dosing) until Day 55 after single and multiple drug dosing. | Area under the concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration |
| Secondary | Cmax | Day 1(Dosing) until Day 55 after single and multiple drug dosing. | Maximum observed plasma concentration |
| Secondary | Tmax | Day 1(Dosing) until Day 55 after single and multiple drug dosing. | Time of the maximum observed plasma concentration |
| Secondary | T½ | Day 1(Dosing) until Day 55 after single and multiple drug dosing. | Apparent terminal elimination half-life |
| Secondary | Vz/F | Day 1(Dosing) until Day 55 after single and multiple drug dosing. | Apparent volume of distribution |
| Secondary | Changes in mean hemoglobin | week 10 | Changes in mean hemoglobin (Hb) relative to baseline during weeks 8 and 10. |
| Secondary | Hemoglobin response | week 10 | Percentage of subjects who met the hemoglobin response after dosing |
| Secondary | E-AUC0-t | Day 1(Dosing) until Day 55 after single and multiple drug dosing. | Area under the EPO concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration |
| Secondary | Emax | Day 1(Dosing) until Day 55 after single and multiple drug dosing. | Maximum observed EPO concentration |
| Secondary | E-Tmax | Day 1(Dosing) until Day 55 after single and multiple drug dosing. | Time of the maximum observed EPO concentration |
| Secondary | Serum lipid | Up to Day 55 | Changes in Serum lipid relative to baseline at weeks 8. |
| Secondary | Indicators of iron | Up to Day 55 | Changes in the Indicators of iron relative to baseline at weeks 8. |
| Secondary | High-sensitivity C-reactive protein | Up to Day 55 | Changes in the High-sensitivity C-reactive protein relative to baseline at weeks 8. |
| Secondary | Reticulocytes | Up to Day 85 | Changes in the mean Reticulocytes relative to baseline after doses. |
| Secondary | VEGF | Up to Day 55 | Changes in the VEGF relative to baseline after doses. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04925661/registered